A. Water

R 68 070: Thromboxane A2 Synthetase Inhibition and Thromboxane A2/Prostaglandin Endoperoxide Receptor Blockade Combined in One Molecule - II. Pharmacological Effects In Vivo and Ex Vivo

P. Janssen, E. Vercammen, F. De Clerck, 1989, Thrombosis and Haemostasis.

Prevention of the “no reflow” phenomenon in the canine heart by mioflazine

W. Flameng, J. Vanhaecke, R. Xhonneux, 2005, Basic Research in Cardiology.

Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist.

R. Reneman, P. Janssen, J. de Cree, 1988, Journal of cardiovascular pharmacology.

Corrigendum to “In vitro experimental models for the risk assessment of antibiotic-induced QT prolongation” [European Journal of Pharmacology 553 (2007) 229–239]

Hua-rong Lu, J. Rohrbacher, A. Hermans, 2007 .

Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.

K. van Ammel, F. De Clerck, A. Van de Water, 1991, Circulation research.

A new method to calculate the beat-to-beat instability of QT duration in drug-induced long QT in anesthetized dogs.

H. R. Lu, Hua-rong Lu, D. Gallacher, 2005, Journal of pharmacological and toxicological methods.

Nebivolol is devoid of intrinsic sympathomimetic activity.

R. Reneman, P. Janssen, A. Van de Water, 1989, European journal of pharmacology.

Cardioprotective effects of mioflazine during 1 h normothermic global ischaemia in the canine heart.

P. Janssen, M. Borgers, P. V. Van Daele, 1984, Cardiovascular research.

Cardioprotective Effects of Lidoflazine During 1‐hour Normothermic Global Ischemia

M. Borgers, W. Daenen, W. Flameng, 1981, Circulation.